Brief: Aquestive Therapeutics Announces That FDA Will Not Require An Advisory Committee Meeting To Discuss New Drug Application For Anaphylm™
04/09/2025 12:01
Aquestive Therapeutics Inc AQST.O: AQUESTIVE THERAPEUTICS ANNOUNCES THAT FDA WILL NOT REQUIRE AN ADVISORY COMMITTEE MEETING TO DISCUSS NEW DRUG APPLICATION FOR ANAPHYLM™ AQUESTIVE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR ANAPHYLM IS JANUARY 31, 2026 Source text: ID:nGNX8SqwGh Further company coverage: AQST.O
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million